# A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

> **NCT06215118** · PHASE1 · RECRUITING · sponsor: **Pfizer** · enrollment: 87 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Elranatamab
- **DRUG:** Iberdomide

## Key facts

- **NCT ID:** NCT06215118
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-20
- **Primary completion:** 2027-04-10
- **Final completion:** 2028-03-09
- **Target enrollment:** 87 (ESTIMATED)
- **Last updated:** 2026-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06215118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06215118, "A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT06215118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*